Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for AirSculpt Technologies, Inc. (NASDAQ: AIRS), a national provider of premium body contouring procedures. Through these documents, investors can review how the company reports its financial condition, operating results, governance changes and capital markets activity.
AirSculpt’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q contain audited and interim financial statements, management’s discussion and analysis, detailed risk factors and information about its single operating segment focused on direct medical procedure services. These filings also discuss the company’s use of non-GAAP measures such as Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, along with reconciliations to GAAP metrics.
Current reports on Form 8‑K disclose material events, including quarterly earnings releases, updates to revenue and Adjusted EBITDA guidance, leadership and board changes, executive employment terms, resignations of officers, and capital structure developments. Recent 8‑K filings, for example, describe the appointment of a new Chief Financial Officer, the election of a Non-Executive Chairman of the Board, executive and board departures, and the announcement of quarterly results.
For those monitoring ownership and compensation, proxy materials and, where applicable, insider transaction reports on Form 4 can provide additional insight into equity awards, performance-based restricted stock units and other elements of the company’s equity incentive plans as referenced in its filings.
Stock Titan enhances this filings feed with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand changes in guidance, capital structure, risk disclosures and governance arrangements. Filings are updated in near real time as they are posted to EDGAR, allowing investors, analysts and other stakeholders to follow AirSculpt’s regulatory reporting history and evaluate AIRS stock using primary source information.
AirSculpt Technologies (AIRS) Q2-25 10-Q highlights:
- Revenue: $44.0 m, -14% YoY; H1-25 revenue $83.4 m, -15% YoY.
- Case volume: 3,392 for the quarter (-14%); revenue per case stable at ~$12.9k.
- Profitability: Adj. EBITDA $5.8 m (13.3% margin vs. 13.5% LY); GAAP net loss $(0.6) m vs. $(3.2) m LY. H1 net loss $(3.4) m.
- Cost actions: Advertising down $3.7 m; $3 m annual overhead cuts; de-novo expansion paused.
- Capital & liquidity: Cash $8.2 m; term-loan $58.8 m (rate 7.8%); leverage covenant amended in Mar-25; $10 m debt pre-payment on 13-Jun-25 funded by $14 m follow-on equity offering (3.6 m shares at $3.80).
- ATM program: 0.12 m shares sold YTD for $0.3 m.
- Balance sheet: Total assets $198.4 m; stockholders’ equity $91.2 m; net debt ~$50.6 m.
- Guidance/strategy: Management focusing on marketing ROI, sales training, new financing options, product innovation and standalone skin-tightening; aims to stabilize same-center performance amid industry softness.
Key risks include declining demand, leverage (LT debt/Adj. EBITDA ≈ 5.0x), tighter covenants, and rising interest margin from July 2025.